- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00446433
A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled,Parallel-Group Study to Evaluate the Safety and Efficacy of CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease
Study Overview
Study Type
Enrollment
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75010
- Hôpital Saint Louis
-
-
-
-
-
Haifa, Israel
- Rambam Hospital
-
Jerusalem, Israel, 91120
- Department of Medicine A, Liver & Gastroenterology Units
-
Tel-Hashomer, Israel, 52621
- Department of gastroenterology and hepatology
-
-
-
-
-
Bristol, United Kingdom, BS2 8HW
- Department of Gastroenterology
-
Cambridge, United Kingdom, CB2 2QQ
- Addenbrookes Hospital
-
Cardiff, United Kingdom, CF 14 4XW
- Department of Medicine
-
London, United Kingdom, NW3 2QG
- Department of Gastroenterology
-
London, United Kingdom, W12 0HS
- Department of Gastroenterology
-
London, United Kingdom, W1N 8AA
- Department of Gastroenterology
-
Manchester, United Kingdom, M13 9WL
- Department of Gastroenterology
-
Middlesex, United Kingdom, HA 1 3UI
- St. Mark's Hospital
-
Newcastle, United Kingdom, NE1 4LP
- Department of Gastroentroerology
-
Nottingham, United Kingdom
-
-
Kent
-
Dartford, Kent, United Kingdom, DA2 8DA
- Department of Gastroenterology
-
-
-
-
Arizona
-
Tucson, Arizona, United States, 85712
- Advanced Clinical Therapeutics
-
-
California
-
Anaheim, California, United States, 92801
- Advanced Clinical Research Institute
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Washington Hospital Center Physicians Office Building
-
-
Illinois
-
Springfield, Illinois, United States, 62794-9248
- Springfield Clinic
-
-
North Carolina
-
Raleigh, North Carolina, United States, 27612
- Wake Research Associates
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female subjects > 12 and < 75 years of age.
- Adolescent and adult female subjects must be of non-childbearing potential (hysterectomy) or be using one highly effective method (e.g., IUD, hormonal contraception, tubal ligation) of birth control during the entire study. Abstinence will be considered an acceptable method of birth control for adolescent females aged 12-17 years who are not sexually active and who the investigator feels will be compliant with this requirement for the 12-week treatment period. Female subjects who are post-menopausal must have had 24 continuous months of amenorrhea.
- Negative pregnancy test for females of child bearing potential.
- A history of Crohn's Disease (CD) of greater than 1-year duration diagnosed and documented by standard clinical, radiographic, endoscopic, histopathological criteria.
- Signs and symptoms of moderately severe CD as defined by a Crohn's Disease Activity Index (CDAI) score of > 220 and < 400.
- Normal thyroid function as documented by normal TSH (thyroid stimulating hormone).
The subject's treatment for CD must be unchanged, as described below:
The start date of the medications listed below must be at least 4 weeks prior to randomization, and the dose must have been unchanged for at least 2 weeks prior to that visit. Medication doses may be decreased but not increased throughout the study. If not currently using these agents, the stop date of any previous treatment with these agents must be at least 4 weeks prior to randomization. The medications are:
- oral or systemic corticosteroids
- metronidazole (Flagyl®)
- sulfasalazine
- oral mesalamine
- oral olsalazine
- topical rectal therapy with corticosteroids or mesalamine
The start date of the medications listed below must be at least 3 months (12 weeks) prior to randomization, and the dose must have been unchanged for at least 4 weeks. Medication doses may be decreased but not increased throughout the study. If not currently using these agents, the stop date of any previous treatment with these agents must be at least 6 weeks prior to randomization. The medications are:
- azathioprine (AZA)
- 6-mercaptopurine (6 MP)
- methotrexate
Subject's screening laboratory test results must meet the following criteria:
- hemoglobin > 8.5 g/dL.
- white blood cells (WBC) > 3.5 x 109 / L.
- neutrophils > 1.5 x 109/L and lymphocytes >0.5 x 109/L.
- platelets > 100 x 109 / L.
- bilirubin, alanine transaminase (ALT), aspartate transaminase (AST) , and alkaline phosphate levels must not be above two times the upper limit of the normal range.
- serum albumin > 3.2 mg /dL for adults (18-75) and serum albumin > 2.8 mg/dL for adolescents between the ages of 12-17.
- serum creatinine < 2.0 mg/dL
- Subjects must be able to adhere to the study visit schedule and other protocol requirements.
- The subject must understand and voluntarily sign an informed consent document. Adolescent subjects under 18 years of age must have parent/guardian consent as evidenced by a signature on the consent form as well as their own assent, as evidenced by signature on the consent form.
- The subject must be at least 25 kg (55 lbs).
Exclusion Criteria:
- Pregnancy or lactation.
- Predisposition to cardiac arrhythmias and history of clinically significant cardiac disease.
- Diagnosis of ulcerative colitis.
- CD that is limited to the stomach and proximal small intestine.
- Known severe fixed symptomatic stenosis or stricture of the small or large intestine.
- Current evidence of bowel obstruction, or history within the 3 months preceding randomization confirmed with objective radiographic or endoscopic evidence of a stricture with resulting obstruction (dilation of the bowel proximal to the stricture observed upon barium enema or an inability to traverse the stricture at endoscopy.
- Subjects who have undergone a proctocolectomy or total colectomy with ileorectal anastomosis; segmental colectomy is permitted.
- Colostomy or ileostomy.
- Subjects with fulminant disease requiring parenteral steroid treatment, hospitalization, or felt to be in imminent need of surgery, i.e. toxic megacolon, active gastrointestinal bleeding, history of significant ulcer disease and/or esophagitis, peritonitis, intestinal obstruction, perforation, or intra-abdominal abscess requiring surgical drainage.
- Subjects requiring intravenous nutritional support with total parenteral nutrition (TPN)/partial parenteral nutrition (PPN) that provides > 50 % of total daily caloric intake.
- Subjects in whom enteral nutrition with elemental or semi-elemental formula comprises more than 50% of their total daily caloric intake. For adolescents between the ages of 12-17, subjects in whom enternal nutrition with elemental or semi-elemental formula comprises more the 75% of their total daily caloric intake.
- Current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, endocrine (including thyroid as documented by an abnormal TSH), pulmonary, cardiac, neurological, or cerebral disease, including the following specific exclusions: uncontrolled diabetes, unstable ischemic heart disease, uncontrolled or recent seizures, autoimmune diseases not related to inflammatory bowel diseases, chronic respiratory insufficiency, or recent cerebral vascular accident (within 2 months of randomization).
Serious infections or history of opportunistic infections; less serious infections within 3 months of randomization, such as acute upper respiratory tract infections (colds) or uncomplicated urinary tract infection are permitted at the discretion of the Investigator. The following are specific exclusions:
- Chronic hepatitis B and C
- Documented HIV infection, ARC (AIDS related complex), AIDS, or immune deficiency.
- Stool examination positive for enteric pathogens (including Clostridium difficile),pathogenic ova, or parasites.
Concomitant or recent medication use as follows:
- Treatment with any other therapeutic agent targeted at reducing TNF-a, e.g., CC-1088, thalidomide, cyclosporine, or pentoxifylline within 4 weeks of randomization, and mycophenolate (Cellcept), infliximab (Remicadeä), Enbrelä, or FK506 (Tacrolimus) within 8 weeks of randomization
- Treatment with interleukin-2 or -10 or other immunomodifier agent within 24 weeks of randomization.
- Requirement of systemic corticosteroid therapy for other disease(s), e.g., asthma. Inhaled steroids for treating asthma are acceptable for this protocol.
- Subjects receiving anticoagulant therapy (other than a total daily aspirin dose of 325 mg or less).
- Subjects having received non CD-directed antibiotic therapy within 2 weeks of randomization. CD-directed antibiotic therapy, for example with ciprofloxacin or metronidazole, is acceptable provided the dose has been stable for the 2 weeks prior to randomization.
- Subjects who have received an investigational drug within 30 days of randomization.
- Subjects with a history of malignancy, except basal cell or squamous cell carcinoma of the skin or cervical carcinoma in situ.
- Dysplasia (low-grade or high-grade) of the colon/small bowel within the last 5 years prior to screening.
- Subjects who, in the judgment of the Investigator, are unwilling or unable to comply with all the protocol-related assessments and procedures, including completion of a daily diary.
- History of alcohol or other drug abuse within 1 year of randomization, or any conditions associated with poor compliance.
- Subjects in whom multiple venipunctures are not feasible due to poor tolerability or lack of easy access.
- Any condition which, in the opinion of the Investigator, places the subject at unacceptable risk if he/she were to participate in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Gastrointestinal Diseases
- Gastroenteritis
- Intestinal Diseases
- Inflammatory Bowel Diseases
- Crohn Disease
- Physiological Effects of Drugs
- Antineoplastic Agents
- Immunologic Factors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Lenalidomide
Other Study ID Numbers
- CC-5013-CD-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Crohn's Disease
-
ProgenaBiomeRecruitingCrohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's Esophagitis | Crohn's | Crohn Disease of Ileum | Crohn Ileitis | Crohn's Disease Relapse | Crohns Disease Aggravated | Crohn Disease in Remission | Crohn's Disease of PylorusUnited States
-
Massachusetts General HospitalAmerican College of GastroenterologyNot yet recruitingInflammatory Bowel Diseases | Crohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's EsophagitisUnited States
-
Richard Burt, MDTerminatedCROHN'S DISEASEUnited States
-
Agomab Spain S.L.RecruitingFibrostenotic Crohn's DiseaseUnited States, Italy, Poland, Spain, Denmark, Austria, Canada, Germany
-
AbbVieActive, not recruitingCrohn's Disease (CD)United States, Belgium, Canada, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, New Zealand, Norway, Poland, Romania, Slovakia, Spain, United Kingdom
-
AbbVieActive, not recruitingCrohn's Disease (CD)United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Romania, Russian Federation, Slo... and more
-
University Hospital, LilleMinistry of Health, FranceTerminatedCrohn's Disease AggravatedFrance
-
TakedaRecruitingCrohn's Disease (CD)United States, Australia, Israel, Belgium, Hungary, Canada, China, Croatia, Czechia, Greece, Italy, Japan, Korea, Republic of, Poland, United Kingdom, Lithuania, Slovakia, Spain
-
Weill Medical College of Cornell UniversityThe Kenneth Rainin FoundationRecruitingCrohn's Disease (CD)United States
Clinical Trials on CC-5013
-
Great Ormond Street Hospital for Children NHS Foundation...Newcastle-upon-Tyne Hospitals NHS TrustCompletedAllogeneic Haematopoietic Stem Cell TransplantationUnited Kingdom
-
Celgene CorporationTerminatedDiffuse Large B-cell LymphomaUnited States, Canada, Australia
-
Celgene CorporationPrologue Research InternationalCompletedNon-Small Cell Lung CancerUnited States
-
Abramson Cancer Center of the University of PennsylvaniaCompleted
-
CelgeneCompleted
-
CelgeneCompletedMyelodysplastic SyndromeUnited States
-
M.D. Anderson Cancer CenterCelgeneCompletedLeukemia | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLLUnited States
-
Washington University School of MedicineCompletedLeukemia, Myeloid, AcuteUnited States
-
M.D. Anderson Cancer CenterCelgene CorporationCompletedMyelodysplastic Syndrome | Acute Myelogenous LeukemiaUnited States
-
CelgeneCompleted